Home  |  Contact

Cellosaurus PANC-1RG7 (CVCL_WS13)

[Text version]
Cell line name PANC-1RG7
Accession CVCL_WS13
Resource Identification Initiative To cite this cell line use: PANC-1RG7 (RRID:CVCL_WS13)
Comments Population: Caucasian.
Doubling time: 33.83 +- 2.15 hours (PubMed=25394408).
Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0480 (PANC-1)
Sex of cell Male
Age at sampling 56Y
Category Cancer cell line
Publications

PubMed=25394408; DOI=10.3892/or.2014.3599
Wang C.-F., Zhang W.-W., Fu M.-J., Yang A.-Q., Huang H.-H., Xie J.-M.
Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression.
Oncol. Rep. 33:383-390(2015)

Cross-references
Cell line databases/resources cancercelllines; CVCL_WS13
Encyclopedic resources Wikidata; Q98128481
Entry history
Entry creation05-Jul-2019
Last entry update05-Oct-2023
Version number9